Celularity Inc. (NASDAQ:CELU - Get Free Report) was the target of a large growth in short interest in April. As of April 30th, there was short interest totalling 595,000 shares, a growth of 51.4% from the April 15th total of 393,100 shares. Currently, 5.6% of the company's stock are sold short. Based on an average daily volume of 72,300 shares, the days-to-cover ratio is currently 8.2 days.
Hedge Funds Weigh In On Celularity
An institutional investor recently raised its position in Celularity stock. IPG Investment Advisors LLC raised its position in shares of Celularity Inc. (NASDAQ:CELU - Free Report) by 97.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 171,695 shares of the company's stock after acquiring an additional 84,928 shares during the period. IPG Investment Advisors LLC owned approximately 0.09% of Celularity worth $38,000 as of its most recent SEC filing. Institutional investors and hedge funds own 19.02% of the company's stock.
Celularity Stock Down 3.3 %
Shares of CELU stock traded down $0.10 on Friday, hitting $2.95. The company's stock had a trading volume of 16,474 shares, compared to its average volume of 45,227. Celularity has a fifty-two week low of $1.59 and a fifty-two week high of $8.90. The firm's fifty day moving average price is $4.42 and its 200-day moving average price is $3.35.
About Celularity
(
Get Free Report)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
Further Reading
Before you consider Celularity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celularity wasn't on the list.
While Celularity currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
